Related Experiment Video

Updated: Jul 15, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Myocardial metabolism and cardiac performance in obesity and insulin resistance

Stacy Banerjee1, Linda R Peterson

  • 1Washington University School of Medicine, Department of Medicine, St. Louis, MO 63110, USA.

Current Cardiology Reports
|April 14, 2007
PubMed

Insights

Obesity, insulin resistance, and type 2 diabetes contribute to heart failure by affecting heart muscle function, independent of coronary artery disease. Understanding these metabolic changes can lead to new treatments for cardiac dysfunction.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Heart Failure Pathophysiology

Background:

  • Obesity, insulin resistance, and type 2 diabetes are established risk factors for heart failure.
  • These conditions are linked to both ischemic and non-ischemic cardiomyopathy.
  • Emerging evidence implicates them in cardiac dysfunction independent of coronary artery disease.

Purpose of the Study:

  • To explore the mechanisms linking obesity, insulin resistance, and diabetes to cardiac dysfunction.
  • To highlight the role of myocardial metabolic alterations in heart failure development.
  • To inform the development of novel therapeutic strategies.

Main Methods:

  • Review of current literature on metabolic pathways in cardiac dysfunction.
  • Analysis of mechanisms underlying heart muscle adaptation and maladaptation.
  • Synthesis of evidence for non-ischemic cardiac effects.

Main Results:

  • Obesity, insulin resistance, and diabetes induce cardiac dysfunction through altered myocardial metabolism.
  • Metabolic changes can be adaptive initially but become maladaptive.
  • These effects contribute to heart failure independent of coronary artery disease.

Conclusions:

  • Metabolic dysfunction is a key driver of heart failure in patients with obesity, insulin resistance, and diabetes.
  • Targeting myocardial metabolism offers a promising therapeutic avenue.
  • Further research into these mechanisms can prevent and treat cardiac dysfunction.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart12:24

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart

Published on: September 28, 2016

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.